Veterinary Medicines

Suxilon 1.5g Granules for Top Dressing

Authorised
  • Suxibuzone
Download as PDF

Product identification

Medicine name:
Danilon equidos 1.5 g Granules for horses and ponies
Suxilon 1.5g Granules for Top Dressing
Active substance:
  • Suxibuzone
Target species:
  • Horse
  • Horse (pony)
Route of administration:
  • In-feed use

Product details

Active substance and strength:
  • Suxibuzone
    1.50
    gram(s)
    /
    10.00
    gram(s)
Pharmaceutical form:
  • Granules
Withdrawal period by route of administration:
  • In-feed use
    • Horse
      • Meat and offal
        no withdrawal period
      • Milk
        no withdrawal period
    • Horse (pony)
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QM01AA90
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • United Kingdom (Northern Ireland)
Package description:
  • (ID2) 600 gram(s): Box with 60 Bag (Paper; Aluminium; PolyEthylene) each with 10 gram(s)
  • (ID1) 180 gram(s): Box with 18 Bag (Paper; Aluminium; PolyEthylene) each with 10 gram(s)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Ecuphar Veterinaria S.L.U.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Esteve Pharmaceuticals S.A.
Responsible authority:
  • The Veterinary Medicines Directorate
Authorisation number:
  • VM 46037/4001
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0192/001
Concerned member states:
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Estonia
  • Hungary
  • Iceland
  • Latvia
  • Lithuania
  • Norway
  • Poland
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 10/08/2022
Download
Lithuanian (PDF)
Published on: 23/11/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."